Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA Members Should Not Depend on Long-Listed Drugs: President Aoki
June 25, 2007
- JGPMA Proposes “Drug Benefit Standard Price” System
June 25, 2007
- Pfizer Most Active in GP Market: MOSS Survey
June 25, 2007
- GENERIC NEWS IN BRIEF
June 25, 2007
- BUSINESS NEWS IN BRIEF
June 25, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 25, 2007
- NEW PRODUCTS
June 25, 2007
- Hemorrhoid Recurrence Rate 16% 1 Year after Zione Treatment
June 25, 2007
- 14 New Kit/Report Products Included in NHI Price List
June 25, 2007
- Teijin Pharma Aims at Entering Home Health Care Business in US, Europe: Mr Ohyagi
June 25, 2007
- JPMA Explains Its Drug Pricing
June 25, 2007
- US Gov't Confirms Opposition to Yearly Revisions of NHI Prices: Policy Initiatives
June 25, 2007
- Price Gaps between Original Drugs and Generics too Large: Mr Mukai of MOF
June 25, 2007
- REGULATORY NEWS IN BRIEF
June 25, 2007
- OPINION：Be the First to Know
June 25, 2007
- Smoking Rate Drops Below 40% in Men for First Time
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(1)
June 25, 2007
- Eisai Licenses Kissei's Glufast in ASEAN Countries
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(2)
June 25, 2007
- Yakult Aims for \33 Bil. Sales by Boosting Sales of Oxaliplatin
June 25, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…